“…Third, the reaction cycle involves multiple enzyme reactions, all representing potential drug-interference points, and fourth, the high molecular mass protein complex (0.8MDa) offers a large drug-binding landscape (Golas et al, 2009). Despite these favorable features, only very few RNA-editing inhibitors have been identified (Liang and Connell, 2010;Moshiri and Salavati, 2010;Katari et al, 2013, Leeder et al, 2015Zimmermann et al, 2016). Moreover, only three studies have systematically searched for RNA-editing inhibiting compounds, which primarily is due to the lack of a robust, high-throughput compatible assay system.…”